Maxwell Biotech Venture Fund Invests in Pivotal Clinical Trial of Oxagen Limited’s Drug Candidate for Asthma Treatment

Published: Oct 04, 2012

MOSCOW--(BUSINESS WIRE)--Maxwell Biotech Venture Fund (MBVF), founded with the help of Russian government-backed RVC, announced today that its investment committee approved the terms and the amount of an investment in Eleventa, a Russian biotech company, which was founded earlier in 2012 to develop and commercialize innovative products for the treatment of asthma and other allergic respiratory diseases.

Back to news